Division of Microbiology, Calgary Laboratory Services, University of Calgary, Calgary, Alberta, Canada.
J Travel Med. 2011 Sep-Oct;18(5):299-303. doi: 10.1111/j.1708-8305.2011.00548.x. Epub 2011 Aug 15.
We previously identified foreign travel as a risk factor for acquiring infections due to CTX-M (active on cefotaxime first isolated in Munich) producing Escherichia coli. The objective of this study was to assess the prevalence of extended-spectrum β-lactamase (ESBL)-producing E coli among stool samples submitted from travelers as compared to non-travelers (a non-traveler had not been outside of Canada for at least 6 months before submitting a stool specimen).
Once a travel case was identified, the next stool from a non-traveler (not been outside of Canada for at least 6 months) was included and cultured on the chromID-ESBL selection media. Molecular characterization was done using polymerase chain reaction and sequencing for bla(CTX-Ms), bla(TEMs), bla(SHVs), plasmid-mediated quinolone-resistant determinants, O25-ST131, phylogenetic groups, pulsed-field gel electrophoresis (PFGE), and multilocus sequencing typing.
A total of 226 individuals were included; 195 (86%) were negative, and 31 (14%) were positive for ESBL-producing E coli. Notably, travelers were 5.2 (95% CI 2.1-31.1) times more likely than non-travelers to have an ESBL-producing E coli cultured from their stool. The highest rates of ESBL positivity were associated with travel to Africa or the Indian subcontinent. Among the 31 ESBL-producing E coli isolated, 22 produced CTX-M-15, 8 produced CTX-M-14, 1 produced CTX-M-8, 12 were positive for aac(6')-Ib-cr, and 8 belonged to clone ST131.
Our study confirms that foreign travel, especially to the Indian subcontinent and Africa, represents a major risk for rectal colonization with CTX-M-producing E coli and contributed to the Worldwide spread of these bacteria.
我们之前已经确定,出国旅行是感染产 CTX-M(对头孢噻肟最初在慕尼黑分离的药物具有活性)的大肠埃希菌的危险因素。本研究的目的是评估旅行者的粪便样本中与非旅行者相比,产超广谱β-内酰胺酶(ESBL)的大肠埃希菌的流行率(非旅行者在提交粪便样本前至少 6 个月未在加拿大境外)。
一旦确定了旅行病例,就会纳入下一个非旅行者(至少 6 个月未在加拿大境外)的粪便样本,并在 chromID-ESBL 选择培养基上进行培养。使用聚合酶链反应和测序对 bla(CTX-Ms)、bla(TEMs)、bla(SHV)、质粒介导的喹诺酮耐药决定因素、O25-ST131、进化群、脉冲场凝胶电泳(PFGE)和多位点序列分型进行分子特征分析。
共纳入 226 人;195 人(86%)为阴性,31 人(14%)为产 ESBL 的大肠埃希菌阳性。值得注意的是,旅行者从粪便中培养出产 ESBL 的大肠埃希菌的可能性是非旅行者的 5.2 倍(95%CI 2.1-31.1)。ESBL 阳性率最高与前往非洲或印度次大陆有关。在 31 株产 ESBL 的大肠埃希菌中,22 株产生 CTX-M-15,8 株产生 CTX-M-14,1 株产生 CTX-M-8,12 株对 aac(6')-Ib-cr 阳性,8 株属于 ST131 克隆。
我们的研究证实,出国旅行,特别是前往印度次大陆和非洲,是直肠定植产 CTX-M 的大肠埃希菌的主要危险因素,并导致这些细菌在全球范围内传播。